References of "Akolekar, R"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailMaternal plasma soluble endoglin at 11-13 weeks's gestation in pre-eclampsia
Foidart, Jean-Michel ULg; Munaut, Carine ULg; Chantraine, Frédéric ULg et al

in Ultrasound in Obstetrics & Gynecology (2010), 35(6), 680-7

Objectives: To examine the performance of screening for preeclampsia (PE) by a combination of maternal factors, soluble endoglin (sEng), pregnancy associated plasma protein A (PAPP-A), placental growth ... [more ▼]

Objectives: To examine the performance of screening for preeclampsia (PE) by a combination of maternal factors, soluble endoglin (sEng), pregnancy associated plasma protein A (PAPP-A), placental growth factor (PlGF) and uterine artery lowest pulsatibility index (L-PI) at 11-13 weeks of gestation. Methods: Uterine artery L-PI, sEng, PAPP-A and PlGF were measured at 11-13 weeks in 90 singleton pregnancies that subsequently developed PE, including 30 that required delivery before 34 weeks (early-PE) and 60 with late-PE, and 180 unaffected controls. Screening performance for PE by maternal factors, sEng, PAPP-A, PlGF and uterine artery L-PI and their combinations was determined. Results: In early-PE, compared to controls, plasma sEng and uterine L-PI were significantly increased and serum PAPP-A and PlGF were decreased. In late-PE, compared to controls, serum PlGF was decreased and uterine L-PI was increased but plasma sEng and serum PAPP-A were not significantly different. In screening for early-PE, the detection rate at a 10% false positive rate was 46.7% for sEng alone and 96.3% for a combination of maternal factors, sEng, PlGF and uterine artery L-PI. Conclusions: Effective screening for early-PE can be provided by a combination of maternal factors, sEng, PlGF and uterine artery L-PI at 11-13 weeks. [less ▲]

Detailed reference viewed: 26 (10 ULg)
Full Text
Peer Reviewed
See detailMaternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia.
Akolekar, R.; De Cruz, J.; Foidart, Jean-Michel ULg et al

in Prenatal Diagnosis (2010), 30(3), 191-7

Objective To investigate the maternal plasma concentration of soluble fms-like tyrosine kinase-1 (sFlt-1) and free vascular endothelial growth factor (free-VEGF) at 11 to 13 weeks of gestation in patients ... [more ▼]

Objective To investigate the maternal plasma concentration of soluble fms-like tyrosine kinase-1 (sFlt-1) and free vascular endothelial growth factor (free-VEGF) at 11 to 13 weeks of gestation in patients destined to develop preeclampsia (PE) and to examine whether any possible differences in maternal plasma levels are related to uterine artery pulsatility index (PI) and maternal serum placental growth factor (PlGF). Methods Plasma free-VEGF, plasma sFlt-1, serum PlGF and uterine artery PI were measured at 11 to 13 weeks in 90 cases that subsequently developed PE and in 180 unaffected controls. Results In the majority of cases of PE and controls the levels of free-VEGF were undetectable. In the pregnancies that developed PE, compared to unaffected controls, uterine artery PI was higher, serum PlGF was lower but there was no significant difference in levels of sFlt-1. Conclusion Measurement of free-VEGF and sFlt-1 in maternal blood at 11 to 13 weeks of gestation is not useful in the prediction of pregnancies destined to develop PE [less ▲]

Detailed reference viewed: 22 (5 ULg)